An emerging role for calcium sensitisation in the treatment of heart failure.
(2005) In Expert Opinion on Investigational Drugs 14(6). p.659-670- Abstract
- Heart failure occurs in 2 - 3% of the adult population in the developed world. With decompensation of cardiac function, haemodynamic stability can be achieved by using intravenous vasodilators, diuretics and inotropes. Unlike traditional inotropes, Ca2+, sensitisers enhance cardiac function without significantly increasing cardiac oxygen consumption, promoting arrhythmia or impairing lusitropy. The most promising drug in this new class is levosimendan, which has a unique dual mechanism; it enhances cardiac output through a Ca2+-dependent stabilisation of cardiac myofilaments and exhibits vasodilatory effects by opening ATP-dependent K+ channels. Clinical trials have demonstrated the beneficial haemodynamic effects of levosimendan, and... (More)
- Heart failure occurs in 2 - 3% of the adult population in the developed world. With decompensation of cardiac function, haemodynamic stability can be achieved by using intravenous vasodilators, diuretics and inotropes. Unlike traditional inotropes, Ca2+, sensitisers enhance cardiac function without significantly increasing cardiac oxygen consumption, promoting arrhythmia or impairing lusitropy. The most promising drug in this new class is levosimendan, which has a unique dual mechanism; it enhances cardiac output through a Ca2+-dependent stabilisation of cardiac myofilaments and exhibits vasodilatory effects by opening ATP-dependent K+ channels. Clinical trials have demonstrated the beneficial haemodynamic effects of levosimendan, and prospective trials are currently underway to confirm its potential benefits on long-term prognosis. Updated guidelines from the European Society of Cardiology advise on how to incorporate levosimendan into care for patients who have acute heart failure. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/142257
- author
- Erhardt, Leif RW LU
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- therapy, heart Failure, calcium sensitiser, clinical trials, inotropes, levosimendan, heart-failure
- in
- Expert Opinion on Investigational Drugs
- volume
- 14
- issue
- 6
- pages
- 659 - 670
- publisher
- Ashley Publications
- external identifiers
-
- wos:000231215200007
- pmid:16004594
- scopus:21244451092
- ISSN
- 1744-7658
- DOI
- 10.1517/13543784.14.6.659
- language
- English
- LU publication?
- yes
- id
- 66338815-c295-4a7e-8407-90563351bbb7 (old id 142257)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16004594&dopt=Abstract
- date added to LUP
- 2016-04-01 11:48:45
- date last changed
- 2022-01-26 18:35:45
@article{66338815-c295-4a7e-8407-90563351bbb7,
abstract = {{Heart failure occurs in 2 - 3% of the adult population in the developed world. With decompensation of cardiac function, haemodynamic stability can be achieved by using intravenous vasodilators, diuretics and inotropes. Unlike traditional inotropes, Ca2+, sensitisers enhance cardiac function without significantly increasing cardiac oxygen consumption, promoting arrhythmia or impairing lusitropy. The most promising drug in this new class is levosimendan, which has a unique dual mechanism; it enhances cardiac output through a Ca2+-dependent stabilisation of cardiac myofilaments and exhibits vasodilatory effects by opening ATP-dependent K+ channels. Clinical trials have demonstrated the beneficial haemodynamic effects of levosimendan, and prospective trials are currently underway to confirm its potential benefits on long-term prognosis. Updated guidelines from the European Society of Cardiology advise on how to incorporate levosimendan into care for patients who have acute heart failure.}},
author = {{Erhardt, Leif RW}},
issn = {{1744-7658}},
keywords = {{therapy; heart Failure; calcium sensitiser; clinical trials; inotropes; levosimendan; heart-failure}},
language = {{eng}},
number = {{6}},
pages = {{659--670}},
publisher = {{Ashley Publications}},
series = {{Expert Opinion on Investigational Drugs}},
title = {{An emerging role for calcium sensitisation in the treatment of heart failure.}},
url = {{http://dx.doi.org/10.1517/13543784.14.6.659}},
doi = {{10.1517/13543784.14.6.659}},
volume = {{14}},
year = {{2005}},
}